echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > CHMP conducts preliminary evaluation of Valneva's COVID-19 vaccine

    CHMP conducts preliminary evaluation of Valneva's COVID-19 vaccine

    • Last Update: 2022-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Valneva's inactivated COVID-19 vaccine candidate VLA2001 has been preliminarily evaluated by the European Committee for Medicinal Products for Human Use (CHMP)
    .


    Following the company's response, the European Medicines Agency (EMA) will provide an approval timeline


    COVID-19 Management

    Valneva expects to receive a positive recommendation from the CHMP for conditional approval of VLA2001 (primary immunization in adults 18 to 55 years of age) by the end of the first quarter of 2022
    .


    Following conditional approval, the company expects to ship to European countries early in the second quarter of this year


    immunity

    A randomized phase III trial comparing the vaccine candidates VLA2001 and AZD12221 showed that compared with AZD1222, patients in the VLA2001 arm had higher levels of neutralizing antibody titers and were generally well tolerated (significantly better than AZD1222)
    .


    VLA2001 is able to induce broad T cell responses against S, M and N proteins


    A randomized phase III trial comparing the vaccine candidates VLA2001 and AZD12221 showed that compared with AZD1222, patients in the VLA2001 arm had higher levels of neutralizing antibody titers and were generally well tolerated (significantly better than AZD1222)


    Thomas Lingelbach, CEO of Valneva, said: "We are satisfied with the initial assessment by CHMP and look forward to providing our response as soon as possible.

    VLA2001 is the only inactivated COVID-19 vaccine in clinical development in Europe"
    .

    The vaccine is designed to actively immunize at-risk groups to prevent symptomatic infection with
    COVID-19 .


    It consists of SARS-CoV-2 inactivated whole virus particles with high S protein density combined with two adjuvants (alum and CpG 1018)


    infection prevention

    This combination has demonstrated high antibody levels in numerous preclinical experiments
    .


    It is expected to meet standard cold chain requirements (2 to 8 degrees Celsius) for easier distribution


    Inactivated vaccines are made by inactivating or killing a disease-carrying virus or bacterium (or a very similar virus or bacterium) with chemicals, heat, or radiation
    .


    This approach uses technology that has been shown to work in humans to produce vaccines at a reasonable scale


     

    Original source:

    Original source:

    https:// href="https://" target="_blank" rel="noopener">https:// https:// Leave a comment here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.